{
    "nct_id": "NCT05077280",
    "official_title": "A Phase II Study of Concurrent Stereotactic Body Radiotherapy With Relatlimab and Nivolumab in Patients With Metastatic Uveal Melanoma",
    "inclusion_criteria": "* measurable metastatic uveal melanoma.\n* No concomitant therapy.\n* Prior PD1 or tebendafesp allowed.\n* Performance status 0-1.\n* No active Hepatitis B.\n* No known HIV infection.\n* WBC>2000, ANC>1500, Hgb >8.\n* Creatinine < 3 x ULN.\n* AST & ALT < 2.5 x ULN Bilirubin < 2 x ULN.\n* Albumin >2.9\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Liver tumor volume > 50%.\n* Active CNS metastases.\n* Pregnancy.\n* Prior therapy with Opdualag or relatlimab\n* Certain autoimmune diseases.\n* Previous liver embolization or radiation.\n* Use of systemic steroids",
    "miscellaneous_criteria": ""
}